Tag Parkinson’s disease

AbbVie announced the launch of PRODUODOPA® in the EU for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia.

AbbVie announced the launch of PRODUODOPA® in the EU for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia, and when available combinations of Parkinson’s medicinal products have not given satisfactory results. PRODUODOPA is the first-and-only…

AbbVie and Cerevel Therapeutics announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates.

AbbVie and Cerevel Therapeutics announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease (PD), and mood disorders. The…